https://www.selleckchem.com/pr....oducts/dss-crosslink
ab. All nonresponders at both 6th and 12th month were using OCS regularly, whereas most of super-responder used the OCS only during exacerbations. Mepolizumab effectively reduced asthma exacerbations, steroid requirement, blood eosinophil counts and improved asthma control, pulmonary function, sinonasal symptoms and quality of life. Our data suggest that mepolizumab would be effective in selected patients in real-life settings. Mepolizumab effectively reduced asthma exacerbations, steroid requirement, blood eosinophil counts and